These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 19412103)

  • 1. Adherence to osteoporosis treatments: room for improvement.
    Warriner AH; Curtis JR
    Curr Opin Rheumatol; 2009 Jul; 21(4):356-62. PubMed ID: 19412103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming problems with adherence to osteoporosis medication.
    Rabenda V; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):677-89. PubMed ID: 21155701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adherence to treatment of osteoporosis: an open question].
    Varenna M; Sinigaglia L
    Reumatismo; 2009; 61(1):4-9. PubMed ID: 19370181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication selection and patient compliance in the clinical management of osteoporosis.
    Inderjeeth CA; Inderjeeth AJ; Raymond WD
    Aust Fam Physician; 2016 Nov; 45(11):814-817. PubMed ID: 27806451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD; Ettinger M
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.
    Hiligsmann M; Boonen A; Rabenda V; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2012 Apr; 12(2):159-66. PubMed ID: 22458617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.
    Reginster JY
    Expert Opin Pharmacother; 2005 Oct; 6(13):2301-13. PubMed ID: 16218890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous zoledronic acid for the treatment of osteoporosis.
    Lewiecki EM
    Curr Osteoporos Rep; 2008 Mar; 6(1):17-23. PubMed ID: 18430396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trial.
    Solomon DH; Gleeson T; Iversen M; Avorn J; Brookhart MA; Lii J; Losina E; May F; Patrick A; Shrank WH; Katz JN
    Osteoporos Int; 2010 Jan; 21(1):137-44. PubMed ID: 19436935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference.
    Beard MK
    Curr Med Res Opin; 2012 Jan; 28(1):141-7. PubMed ID: 22103779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
    Danese MD; Badamgarav E; Bauer DC
    J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
    Cramer JA; Silverman S
    Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.
    Moro-Alvarez MJ; Díaz-Curiel M
    Clin Interv Aging; 2008; 3(2):227-32. PubMed ID: 18686745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence with medications used to treat osteoporosis: behavioral insights.
    Schousboe JT
    Curr Osteoporos Rep; 2013 Mar; 11(1):21-9. PubMed ID: 23334573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence, patient preference and dosing frequency: understanding the relationship.
    Reginster JY; Rabenda V; Neuprez A
    Bone; 2006 Apr; 38(4 Suppl 1):S2-6. PubMed ID: 16520104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study of two different information-based interventions on the management of osteoporosis in minimal and moderate trauma fractures.
    Bliuc D; Eisman JA; Center JR
    Osteoporos Int; 2006; 17(9):1309-17. PubMed ID: 16804739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of adherence to medications for the treatment of osteoporosis.
    Gold DT; Silverman S
    Curr Osteoporos Rep; 2006 Mar; 4(1):21-7. PubMed ID: 16527004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates for the prevention and treatment of osteoporosis.
    Maraka S; Kennel KA
    BMJ; 2015 Sep; 351():h3783. PubMed ID: 26333528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral bisphosphonate compliance and persistence: a matter of choice?
    Silverman SL; Schousboe JT; Gold DT
    Osteoporos Int; 2011 Jan; 22(1):21-6. PubMed ID: 20458571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost‏.
    Chodick G; Moser SS; Goldshtein I
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):359-70. PubMed ID: 27015247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.